Articles tagged "Hepatocellular carcinoma"

2021 American Transplant Congress
Immunotherapy of Dc-cik Cells in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation
S. Hsu, L. Jeng, H. Yang, A. Thorat
China Medical University Hospital, Taichung, Taiwan
*Purpose: Dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic resistance in some…
2020 American Transplant Congress
HCC Liver Transplantation Waitlist Dropout Rates before and after the Mandated Six-Month Wait-Time
M. LaVere¹, K. Robichaux², J. Buggs³, E. Rogers³, S. Nyce⁴, A. Kumar¹, J. Sokolich³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴University of Tampa, Tampa, FL
*Purpose: Studies have shown significant improvement in hepatocellular carcinoma (HCC) recurrence rates following the UNOS implementation of a six-month wait period. However, few have examined…
2020 American Transplant Congress
Comparing Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: An Analysis of UNOS Registry
T. Kitajima¹, D. Moonka², S. Yeddula¹, M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹, S. Nagai¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Because of possible short waiting time, living donor liver transplantation (LDLT) for HCC may provide survival benefit compared to deceased donor LT (DDLT). This…
2020 American Transplant Congress
Living Donor Liver Transplantation Should Be Considered Cautiously in Recurrent Hepatocellular Carcinoma within the Milan Criteria after Curative Liver Resection
J. Kim¹, N. Yi², G. Choi¹, C. D. Kwon³, K. Lee², K. Suh², J. Joh¹
¹Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, ²Division of HBP Surgery, Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, ³Department of Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH
*Purpose: Insufficient data are available about patient survival following different treatments for recurrent hepatocellular carcinoma (HCC) after primary hepatectomy. We retrospectively evaluated the effects of…
2020 American Transplant Congress
Hepatocellular Carcinoma Recurrence after Severe Acute Cellular Rejection
M. Najjar¹, O. Perez¹, K. Bruestle¹, A. Qian¹, P. Jiang¹, A. Srivastava¹, Y. Saenger¹, E. Verna¹, E. Zheng¹, A. Mathur¹, A. Griesemer¹, K. Halazun², B. Samstein², T. Kato¹, J. Emond¹
¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: The interplay between acute cellular rejection (ACR), immunosuppression and hepatocellular carcinoma (HCC) recurrence in patients who underwent liver transplantation (LT) for HCC is still…
2020 American Transplant Congress
Synergistic Anticancer Effect of Metformin in Combination with Immunosuppressant on Hepatocellular Carcinoma Cell Lines
S. Suh¹, Y. Choi¹, K. Lee²
¹Surgery, Chung-Ang University, College of Medicine, Seoul, Korea, Republic of, ²Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of
*Purpose: After liver transplantation (LT), immunosuppression is needed to avoid rejection and graft loss, however, it can stimulate hepatocellular carcinoma (HCC) recurrence and progression. Previous…
2020 American Transplant Congress
Outcomes Following Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma: A Matched Analysis
M. L. Holzner¹, F. Parvin-Nejad², K. Fei³, S. Florman¹, M. E. Schwartz¹, P. Tabrizian¹
¹Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Mixed hepatocellular-cholangiocarcinoma (HCC-CC) is a biphenotypic liver cancer thought to have unfavorable tumor biology and a poor prognosis. Surgical outcomes of HCC-CC remain unclear.…
2020 American Transplant Congress
Multimodal Strategy for Hepatocellular Carcinoma in the Elderly: To Transplant or Not to Transplant
M. Najjar¹, O. Perez¹, J. Zou¹, S. Sun¹, K. Bruestle¹, P. Jiang¹, E. Verna¹, E. Zheng¹, Y. Saenger¹, A. Mathur¹, A. Griesemer¹, B. Samstein², T. Kato¹, K. Halazun², J. Emond¹
¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: Liver transplantation LT for HCC is curative but entails increased risk and is limited by organ scarcity. Alternative approaches such as locoregional therapy (LRT)…
2020 American Transplant Congress
Left Lobe Living Donor Liver Transplantation Using Rapid Procedure in a Cirrhotic Patient with Hepatocellular Carcinoma with a GRWR of 0.35
D. Balci¹, O. Kirimker¹, M. Kologlu², U. Goktug¹, E. Ustuner³, S. Karadag⁴, E. Er⁵, G. Cinar⁶, M. Bayar⁴, A. Yilmaz⁴, A. Azap⁶, K. Karayalcin¹
¹General Surgery and Transplantation, Ankara University, Ankara, Turkey, ²Pediatric Surgery and Transplantation, Ankara University, Ankara, Turkey, ³Radiology, Ankara University, Ankara, Turkey, ⁴Anesthesiology, Ankara University, Ankara, Turkey, ⁵Gastroenterology, Ankara University, Ankara, Turkey, ⁶Infectious Disease, Ankara University, Ankara, Turkey
*Purpose: Here, we describe a new approach using Rapid Procedure, a 2 stage hepatectomy technique, with living donor liver transplantation (LDLT) in the cirrhotic setting…
2020 American Transplant Congress
Factors Associated with Hepatocellular Carcinoma Understaging for Liver Transplantation, and Variation in Understaging by Transplant Center
N. Mahmud¹, M. Hoteit¹, D. Goldberg²
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) may be cured by liver transplantation (LT) in selected patients, though recurrence rates remain high. Patients who are reported as within…

« Previous Page
1
…
4
5
6
7
8
…
23
Next Page »